Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.89 |
| ▸ | RAMP1 | O60894 | 13/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377695 | 0.95 | CALCRL (0.99) | CALCRLRAMP1 | |
| Hydrochloric Acid SCHEMBL3710375 | 0.94 | CALCRL (1.00) | CALCRLRAMP1 | |
| SCHEMBL6379804 | 0.92 | CALCRL (0.85) | CALCRLRAMP1 | |
| SCHEMBL6379562 | 0.90 | CALCRL (0.84) | CALCRLRAMP1 | |
| SCHEMBL5020102 | 0.89 | CALCRL (0.87) | CALCRLRAMP1 | |
| SCHEMBL6377510 | 0.87 | CALCRL (0.84) | CALCRLRAMP1 | |
| Atogepant SCHEMBL22259545 | 0.86 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL31611055 | 0.86 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL19750880 | 0.86 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL4570348 | 0.86 | CALCRL (1.00) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821407-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2821407-A1 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck Sharp & Dohme Corp. (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2638042-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.